The Effect of SGLT2 Inhibitor Dapagliflozin on BMI in Female Adolescents with Type 1 Diabetes

被引：0
|
作者：
Roman, R. [1 ]
Valdivia, N. [2 ]
Ruiz, S. [3 ]
机构：
[1] Univ Antofagasta, Hosp Reg Antofagasta, Antofagasta, Chile
[2] Univ Antofagasta, Antofagasta, Chile
[3] Hosp Reg Antofagasta, Antofagasta, Chile
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2015年 / 84卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O15
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [31] Influence on urination of SGLT2 inhibitor in type 2 diabetes
    Sasaki, Junko
    Shikuma, Junpei
    Ito, Rokuro
    Odawara, Masato
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S98 - S98
  • [32] SGLT2 inhibitor shows promise in type 2 diabetes
    Nature Reviews Drug Discovery, 2010, 9 (3) : 182 - 182
  • [33] SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
    Chen, Huan
    Birnbaum, Yochai
    Ye, Regina
    Yang, Hsiu-Chiung
    Bajaj, Mandeep
    Ye, Yumei
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (06) : 1091 - 1108
  • [34] SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
    Huan Chen
    Yochai Birnbaum
    Regina Ye
    Hsiu-Chiung Yang
    Mandeep Bajaj
    Yumei Ye
    Cardiovascular Drugs and Therapy, 2022, 36 : 1091 - 1108
  • [35] Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus
    Rodrigues, E. A.
    Dionizio, A.
    Rosa, C. M.
    Campos, D. H. S.
    Damatto, F. C.
    Borim, P. A.
    Pagan, L. U.
    Oliveira, J. P. G.
    Souza, L. M.
    Gatto, M.
    Araujo, T. T.
    Buzalaf, M. A.
    Cunha, T. M.
    Okoshi, K.
    Okoshi, M. P.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [36] Case History: Forxiga™ (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
    Washburn, William N.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 363 - 382
  • [37] SGLT2 IN TYPE 1 DIABETES - EFFICACY
    Mathieu, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A6 - A6
  • [38] Effect of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, on Systolic Blood Pressure in Patients with Type 2 Diabetes
    Hardin, Marquette
    Davies, Michael
    Carroll, Amy
    Umpierrez, Guillermo
    CIRCULATION, 2024, 150
  • [39] Exposure-efficacy outcome modeling for dapagliflozin, an orally selective SGLT2 inhibitor, in patients with type 2 diabetes
    Feng, Yan
    Zhang, Liping
    List, James F.
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1114 - 1114
  • [40] Treatment with SGLT2 inhibitor dapagliflozin for non-alcoholic steatohepatitis patients complicated with type 2 diabetes mellitus
    Tobita, Hiroshi
    Sato, Shuiti
    Miyake, Tatuya
    Yazaki, Tomotaka
    Isoda, Kazuki
    Mishiro, Tuyoshi
    Ishihara, Shunji
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 388 - 388
12345